


Using digital and drug delivery innovations to improve adherence in asthma

Background

Poor adherence and improper inhaler technique may:



Reasons for poor adherence vary

Unintentional non-adherence examples⁴:

- **Misunderstanding** about instructions
- Forgetfulness, cognitive impairment or presence of psychological problems
- No **daily routine**

Intentional non-adherence examples⁴:

- Concern about **side effects**
- Treatment viewed as **unnecessary**
- Resent **impact on daily life**

Medication/regimen factors examples:

- Incorrect inhaler use
 - **50% of patients are unable to use their inhaler correctly** even with training⁵
- Burdensome, complex or costly treatment regimens

Patient concerns and beliefs should be discussed in order to understand their medication-taking behaviour⁴

Adequate follow-up is essential to optimise adherence among patients with asthma

Evidence-based interventions to increase adherence⁴ include technical, behavioural and educational interventions

Simplified dosing regimens (technical)

Once-daily rather than twice-daily dosing

Inhalation reminders (technical/behavioural)

Remind patients of upcoming doses or alert them to missed doses

Shared decision making (behavioural)

Between patient and doctor, taking into account the patient's preferred medication and dosing

Patient training (educational)

Inhaler skills training and follow up checks on technique

Home visits (behavioural/educational)

By trained asthma nurses

Digital and drug delivery innovations

Inhaler devices that address patient needs

- Should be consistent and simple to use⁶

Inhaler tracking sensors used with mobile Health (mHealth) apps provide patients with^{7–9}

- Inhalation confirmation
- Medication reminders
- Access to real data
- Such technologies may lead to significant improvements in medication adherence and asthma control¹⁰

Telemedicine

- Improves patient **awareness¹¹**
- Facilitates shared decision-making, shown to improve adherence
- Encourages **self-management¹¹**

mHealth applications

- Enable disease understanding and self management⁵
- Improve asthma control and treatment adherence^{2,12,13}

References
1. D'Itri R, et al. Respir Med 2020;162:105959. 2. Asthma UK. Available from: <https://www.asthma.org.uk/1291916/globalassets/get-involved/external-affairs-campaigns/publications/connected-asthma/connected-asthma-aug-2016.pdf> (Last accessed November 2019). 3. Engelkes M, et al. Eur Respir J 2016;45:396–407. 4. Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available from www.ginasthma.org (Last accessed December 2019). 5. Azzi E, et al. NPJ Prim Care Respir Med 2017;27:23. 6. Ibrahim M, et al. Med Devices. 2015;8:131–139. 7. Jeminiwa R, et al. Resp Med 2019;149:59–68. 8. Merchant RK, et al. J Allergy Clin Immunol Pract 2016;4:455–463. 9. Howard S, et al. BMJ Open Resp Res 2016;3:e000159. 10. Chan AH, et al. Lancet Respir Med 2015;3:210–219. 11. Morrison D, et al. Chron Respir Dis 2017;14:407–404. 12. Kosse RC, et al. Respir Med 2019;149:45–51. 13. Farzandipour M, et al. App Clin Inform 2017;3:1068–1081.

© 2020 Novartis Pharma AG 2020
GLRESP/OVM149/0094
May 2020

Novartis Pharma AG
CH-4056 Basel, Switzerland
www.novartis.com